SCHEMBL10104480

SCHEMBL10104480

Cc1cc(CN2CCCCC2)c(C)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.43
ALDH1A1 P00352 7/20 0.43
POLB P06746 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NR1H2 P55055 1/20 0.40
CRHR1 P34998 2/20 0.40
SIGMAR1 Q99720 1/20 0.40
CACNA1B Q00975 1/20 0.39
TDP1 Q9NUW8 3/20 0.39
ATM Q13315 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104533 0.98 KDM4E (0.44) KDM4EALDH1A1POLBCNR1CNR2
SCHEMBL10104460 0.85 KDM4E (0.43) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL10104478 0.85 CNR1 (0.53) KDM4EPOLBCNR1CNR2KMT2A
SCHEMBL10104479 0.84 KDM4E (0.43) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL10104431 0.83 KDM4E (0.43) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL13038515 0.83 KMT2A (0.50) KDM4EALDH1A1KMT2AMEN1TSHR
SCHEMBL14426353 0.81 KDM4E (0.50) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL25745797 0.81 NR1H2 (0.54) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL10104525 0.81 MEN1 (0.44) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL10104470 0.80 KDM4E (0.46) KDM4EALDH1A1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 KDM4E 2715/4885ALDH1A1 175/4885POLB 3682/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 KDM4E 1224/4885ALDH1A1 860/4885POLB 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.